[Cefuroxime axetil--efficiency and safety for treatment of upper airways and middle ear infections in children].
The study aimed at assessing the clinical efficiency, safety, and tolerance of cefuroxime axetil suspension in the treatment of children with the acute upper respiratory infections and/or the acute otitis media. The trial was open, multicenter, involving 304 children aged between 3 months and 12 years. They were recruited from 18 general practice centers in Poland. Children were given cefuroxime axetil suspension in the dose of 10 mg/kg body weight (upper respiratory) or 15 mg/kg otitis media. max. 250 mg) bid. Children were examined prior to the treatment, 3-4 days following the start of therapy, 1-2 days after completion of the treatment, and followed-up for 14 days. Post-therapy examination has shown 93% cure rate. During the follow-up period 0.77% of patients relapsed. Only minor adverse reactions were reported by 4.9% of patients. Most common complaint was vomiting. Cefuroxime axetil suspension was safe and effective therapy in the acute upper respiratory infections and the acute otitis media in childhood.
Barliński
J
J
D002444:Cefuroxime / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D010033:Otitis Media / Q000188:drug therapy*; D011355:Prodrugs / Q000009:adverse effects / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy*
D011355:Prodrugs; D002444:Cefuroxime; C040738:cefuroxime axetil
Cefuroksym aksetyl w ambulatoryjnym leczeniu zakazeń górnych dróg oddechowych u dzieci.